AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28770894 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Weight Support (BWS)
Number of subjects: 0
Study 28770894 — intervention group
Group type: COMPARATOR
Intervention: No Body Weight Support (no-BWS)
Number of subjects: 0
Study 25692556 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm long implants (test group)
Number of subjects: 45
Study 25692556 — intervention group
Group type: COMPARATOR
Intervention: 10 mm long implants (control group)
Number of subjects: 45
Study 25692556 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 6 mm and 10 mm implants
Number of subjects: 45
Study 25222614 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-step early intervention program (at 33 and 42 weeks after conception and at 4 months' corrected age)
Number of subjects: 26
Study 25222614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 22343119 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-postoperative isophane insulin for evening blood glucose ≥140 mg/dl
Number of subjects: 50
Study 22343119 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control group (short-acting insulin and/or oral antidiabetic agents for blood glucose ≥180-250 mg/dl)
Number of subjects: 50
Study 19587321 — intervention group
Group type: EXPERIMENTAL
Intervention: Spastic-paretic motoneurons
Number of subjects: 0
Study 19587321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-threshold motor units in spastic-paretic muscles
Number of subjects: 0
Study 19587321 — intervention group
Group type: COMPARATOR
Intervention: Lower-threshold motor units in contralateral muscles
Number of subjects: 0
Study 19587321 — intervention group
Group type: COMPARATOR
Intervention: Lower-threshold motor units in healthy control muscles
Number of subjects: 0
Study 17503748 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system for estimating drug exposure and interpreting pharmacokinetic data for LPV
Number of subjects: 199
Study 17503748 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system for estimating drug exposure and interpreting pharmacokinetic data for EFV
Number of subjects: 199
Study 17503748 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system recommendations for LPV
Number of subjects: 199
Study 17503748 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system recommendations for EFV
Number of subjects: 199
Study 15355822 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 1g/day for 14 days
Number of subjects: 113
Study 15355822 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 113
Study 11592603 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (9 million units three times per week) and lamivudine (100 mg/daily) for 24 weeks
Number of subjects: 151
Study 11592603 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (100 mg/daily) for 52 weeks
Number of subjects: 151
Study 11592603 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b and lamivudine combination therapy
Number of subjects: 151
Study 11592603 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 151
Study 9538976 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 10
Study 9538976 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin (HR)
Number of subjects: 10
Study 9538976 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro (LP) and Human regular insulin (HR)
Number of subjects: 10
Study 7628184 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg/day
Number of subjects: 15
Study 7628184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2116086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium (0.6 mg/kg per day in four intravenous doses)
Number of subjects: 80
Study 2116086 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline placebo
Number of subjects: 80
Study 323387 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 24
Study 323387 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 24
Study 30578048 — intervention group
Group type: EXPERIMENTAL
Intervention: RECELL treatment (combined with widely meshed STSG)
Number of subjects: 30
Study 30578048 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (standard meshed STSG)
Number of subjects: 30
Study 30578048 — intervention group
Group type: EXPERIMENTAL
Intervention: RECELL treatment
Number of subjects: 30
Study 30578048 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 30
Study 30578048 — intervention group
Group type: EXPERIMENTAL
Intervention: RECELL treatment and Control treatment
Number of subjects: 30
Study 28012692 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee intake with 89 mg CGA
Number of subjects: 39
Study 28012692 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee intake with 310 mg CGA
Number of subjects: 39
Study 28012692 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified 5-CQA (450 mg)
Number of subjects: 39
Study 28012692 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 39
Study 25549166 — intervention group
Group type: EXPERIMENTAL
Intervention: ITE EMHP
Number of subjects: 12
Study 25549166 — intervention group
Group type: EXPERIMENTAL
Intervention: OTE EMHP
Number of subjects: 12
Study 25549166 — intervention group
Group type: COMPARATOR
Intervention: Open-ear
Number of subjects: 12
Study 25549166 — intervention group
Group type: COMPARATOR
Intervention: Non-training EMHP
Number of subjects: 12
Study 23981511 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (25-100 mg daily based on weight)
Number of subjects: 12
Study 23981511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21467563 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (n = 25)
Number of subjects: 47
Study 21467563 — intervention group
Group type: COMPARATOR
Intervention: Continuous posterior lumbar plexus block (n = 22)
Number of subjects: 47
Study 20137620 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenapax (induction therapy)
Number of subjects: 30
Study 20137620 — intervention group
Group type: COMPARATOR
Intervention: Regular immunosuppressive therapy (control group)
Number of subjects: 30
Study 18090877 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 11
Study 15012174 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporin (CsA) with mycophenolate mofetil (2g daily) and prednisone (0.5-1 mg/kg daily)
Number of subjects: 67
Study 15012174 — intervention group
Group type: COMPARATOR
Intervention: Bayesian predictive performance for the model developed
Number of subjects: 67
Study 11404230 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol (15 mg)
Number of subjects: 10
Study 11404230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9715183 — intervention group
Group type: EXPERIMENTAL
Intervention: I:E ratio of 1:1
Number of subjects: 8
Study 9715183 — intervention group
Group type: EXPERIMENTAL
Intervention: I:E ratio of 3:1
Number of subjects: 8
Study 9331118 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant paclitaxel (200 mg/m2/3 hour, day 1) and carboplatin (AUC 5, day 2)
Number of subjects: 5
Study 2010565 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (8 g for 21 days)
Number of subjects: 12
Study 2010565 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (identical-looking capsules for 21 days)
Number of subjects: 12
Study 2010565 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg single dose)
Number of subjects: 12
Study 7124629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg 3 times daily)
Number of subjects: 32
Study 7124629 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg 3 times daily)
Number of subjects: 32
Study 7124629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31957468 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 247
Study 31957468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 31477157 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART WASHOKU meal
Number of subjects: 21
Study 31477157 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 21
Study 27729164 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive intra-articular 20 mL of bupivacaine 0.5% injection
Number of subjects: 42
Study 27729164 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive periacetabular 20 mL of bupivacaine 0.5% injection
Number of subjects: 42
Study 27729164 — intervention group
Group type: COMPARATOR
Intervention: Total analgesic consumption
Number of subjects: 42
Study 26924418 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-No(®) device
Number of subjects: 660
Study 24909413 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Sedation (DS) using propofol
Number of subjects: 21
Study 24909413 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 21
Study 22304690 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 165
Study 22304690 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS (placebo)
Number of subjects: 165
Study 20498251 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 23
Study 20498251 — intervention group
Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 23
Study 18727076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 16
Study 18727076 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 16
Study 15911188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic specific diabetes education
Number of subjects: 45
Study 12870691 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen of antituberculosis chemotherapy
Number of subjects: 0
Study 12870691 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen containing isoniazid, rifampicin, and ciprofloxacin
Number of subjects: 0
Study 12870691 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 0
Study 10229720 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 206
Study 10229720 — intervention group
Group type: COMPARATOR
Intervention: General Ward (GW)
Number of subjects: 206
Study 9175240 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin supplement (15 g/day)
Number of subjects: 20
Study 9175240 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 g/day)
Number of subjects: 20
Study 1531821 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 72
Study 1531821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 4002804 — intervention group
Group type: COMPARATOR
Intervention: Indapamide (2.5 mg per day)
Number of subjects: 58
Study 4002804 — intervention group
Group type: EXPERIMENTAL
Intervention: Muzolimine (20 mg per day)
Number of subjects: 58
Study 31524143 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-long non-coding RNA signature
Number of subjects: 493
Study 29609926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Group (LDG): Two 90-min yoga classes plus three 30-min homework sessions weekly for 12 weeks.
Number of subjects: 32
Study 29609926 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Group (HDG): Three 90-min yoga classes plus four 30-min homework sessions weekly for 12 weeks.
Number of subjects: 32
Study 29609926 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 32
Study 27993164 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional development (PD) intervention for early childhood educators
Number of subjects: 90
Study 27993164 — intervention group
Group type: COMPARATOR
Intervention: Typical classroom practice (Control)
Number of subjects: 90
Study 25831644 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Limberg's flap closure
Number of subjects: 60
Study 25831644 — intervention group
Group type: COMPARATOR
Intervention: Excision and primary closure
Number of subjects: 60
Study 22374639 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise before resistance exercise (AR)
Number of subjects: 12
Study 22374639 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise before aerobic exercise (RA)
Number of subjects: 12
Study 19028741 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy plus 0.05% isotonic Indocyanine Green (ICG)‐assisted ILM peeling
Number of subjects: 78
Study 19028741 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy plus 0.15% Trypan Blue (TB)‐assisted ILM peeling
Number of subjects: 78
Study 19028741 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy alone without retinal surface manipulation
Number of subjects: 78
Study 18158672 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIMEDS' CVS module
Number of subjects: 50
Study 18158672 — intervention group
Group type: COMPARATOR
Intervention: Existing CVS resources
Number of subjects: 50
Study 15101859 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (50 micro g kg(‐1) loading dose, followed by intravenous morphine-PCA)
Number of subjects: 64
Study 15101859 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue medication (1 mg of morphine)
Number of subjects: 64
Study 15101859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea incidence
Number of subjects: 64
Study 11194215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet
Number of subjects: 32
Study 11194215 — intervention group
Group type: COMPARATOR
Intervention: Ordinary sodium diet
Number of subjects: 32
Study 11194215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium sensitivity index
Number of subjects: 32
Study 11194215 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure readings <130/85 mmHg
Number of subjects: 32
Study 11194215 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of urinary albumin
Number of subjects: 32
Study 8126472 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin 0, 6, 12, and 24 micrograms/kg
Number of subjects: 0
Study 8126472 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin 0, 15, 30, 60, and 120 micrograms/kg
Number of subjects: 0
Study 2882060 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for 4 weeks)
Number of subjects: 0
Study 2882060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29548304 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated medication management model (CoMM) involving practical nurses and clinical pharmacists
Number of subjects: 191
Study 29548304 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional triage meeting
Number of subjects: 191
Study 29548304 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacists conducting medication reviews
Number of subjects: 191
Study 29548304 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation and follow-up of medication changes
Number of subjects: 191
Study 28473063 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP) diet (1.5 g•kg‐1•d‐1 protein)
Number of subjects: 32
Study 28473063 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (0.8 g•kg‐1•d‐1 protein)
Number of subjects: 32
Study 28473063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (HP and normal protein)
Number of subjects: 32
Study 26287955 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 87
Study 26287955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 87
Study 26287955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 87
Study 23340711 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychosocial treatment
Number of subjects: 506
Study 18272264 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Systems containing MPL/QS21 (AS02B, AS02V, AS01B)
Number of subjects: 100
Study 18272264 — intervention group
Group type: COMPARATOR
Intervention: CpG oligonucleotide
Number of subjects: 100
Study 16481707 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lindane cream
Number of subjects: 99
Study 16481707 — intervention group
Group type: COMPARATOR
Intervention: 5% permethrin cream
Number of subjects: 99
Study 12582352 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose clindamycin (600 mg)
Number of subjects: 70
Study 12582352 — intervention group
Group type: COMPARATOR
Intervention: 24-hour clindamycin prophylaxis (600 mg total)
Number of subjects: 70
Study 10701819 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg once daily
Number of subjects: 162
Study 10701819 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily
Number of subjects: 162
Study 9337609 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical daily dose of caffeine (400-1000 mg)
Number of subjects: 24
Study 9337609 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of caffeine in excess of daily consumption
Number of subjects: 24
Study 7903212 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tertatolol (T) once daily
Number of subjects: 230
Study 7903212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 3119650 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (100 micrograms) injected iv on the fifth day of consecutive cycles after an ovulatory cycle
Number of subjects: 10
Study 3119650 — intervention group
Group type: COMPARATOR
Intervention: GnRH (100 micrograms) injected iv on the fifth day of consecutive cycles after an anovulatory cycle
Number of subjects: 10
Study 29860937 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib alone (50 mg daily in cycles of 28 days on and 14 days off)
Number of subjects: 450
Study 29860937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrectomy followed by sunitinib (50 mg daily in cycles of 28 days on and 14 days off)
Number of subjects: 450
Study 29860937 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib alone
Number of subjects: 450
Study 29860937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrectomy followed by sunitinib
Number of subjects: 450
Study 29860937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib alone and Nephrectomy followed by sunitinib
Number of subjects: 450
Study 26444773 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory group intervention
Number of subjects: 219
Study 26444773 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 219
Study 26112885 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation with defibrillation (DF) testing, n = 540
Number of subjects: 1077
Study 26112885 — intervention group
Group type: COMPARATOR
Intervention: ICD implantation without defibrillation (DF) testing, n = 537
Number of subjects: 1077
Study 26112885 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation with DF testing, n = 540
Number of subjects: 1077
Study 26112885 — intervention group
Group type: COMPARATOR
Intervention: ICD implantation without DF testing, n = 537
Number of subjects: 1077
Study 21953134 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized cognitive training (COGPACK)
Number of subjects: 116
Study 21953134 — intervention group
Group type: COMPARATOR
Intervention: Routine occupational therapy
Number of subjects: 116
Study 21953134 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group program (8 sessions within 4 weeks)
Number of subjects: 116
Study 21953134 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 9 months
Number of subjects: 116
Study 21356050 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (immobilisation in a sling at the side in internal rotation for 6 weeks or until clinical or radiological union)
Number of subjects: 300
Study 21356050 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (surgical treatment using the Acumed clavicle fixation system)
Number of subjects: 300
Study 21356050 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 300
Study 21356050 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 300
Study 19175551 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied muscle tension conditions (various muscle groups)
Number of subjects: 1059
Study 19175551 — intervention group
Group type: COMPARATOR
Intervention: Donation as usual (control group)
Number of subjects: 1059
Study 18235928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundoplication with division of short gastric vessels (Group B)
Number of subjects: 90
Study 18235928 — intervention group
Group type: COMPARATOR
Intervention: Fundoplication without division of short gastric vessels (Group A)
Number of subjects: 90
Study 18235928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 90
Study 14769685 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release paclitaxel-eluting stents (SR)
Number of subjects: 427
Study 14769685 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-release paclitaxel-eluting stents (MR)
Number of subjects: 427
Study 14769685 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 427
Study 11794698 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustered dosage (5 consecutive daily infusions at 5-week intervals)
Number of subjects: 20
Study 11794698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclustered dosage (1 infusion weekly)
Number of subjects: 20
Study 11794698 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 20
Study 9426718 — intervention group
Group type: EXPERIMENTAL
Intervention: BTA TRAK assay
Number of subjects: 216
Study 9426718 — intervention group
Group type: COMPARATOR
Intervention: Voided urine cytology (VUC)
Number of subjects: 216
Study 9426718 — intervention group
Group type: COMPARATOR
Intervention: Bard BTA test (BTA)
Number of subjects: 216